Cholera outbreak in Forcibly Displaced Myanmar National (FDMN) from a small population segment in Cox's Bazar, Bangladesh, 2019.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
02
02
2021
accepted:
01
07
2021
entrez:
22
9
2021
pubmed:
23
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Bangladesh experienced a sudden, large influx of forcibly displaced persons from Myanmar in August 2017. A cholera outbreak occurred in the displaced population during September-December 2019. This study aims to describe the epidemiologic characteristics of cholera patients who were hospitalized in diarrhea treatment centers (DTCs) and sought care from settlements of Forcibly Displaced Myanmar Nationals (FDMN) as well as host country nationals during the cholera outbreak. Diarrhea Treatment Center (DTC) based surveillance was carried out among the FDMN and host population in Teknaf and Leda DTCs hospitalized for cholera during September-December 2019. During the study period, 147 individuals with cholera were hospitalized. The majority, 72% of patients reported to Leda DTC. Nearly 65% sought care from FDMN settlements. About 47% of the cholera individuals were children less than 5 years old and 42% were aged 15 years and more. Half of the cholera patients were females. FDMN often reported from Camp # 26 (45%), followed by Camp # 24 (36%), and Camp # 27 (12%). Eighty-two percent of the cholera patients reported watery diarrhea. Some or severe dehydration was observed in 65% of cholera individuals. Eighty-one percent of people with cholera received pre-packaged ORS at home. About 88% of FDMN cholera patients reported consumption of public tap water. Pit latrine without water seal was often used by FDMN cholera individuals (78%). Vigilance for cholera patients by routine surveillance, preparedness, and response readiness for surges and oral cholera vaccination campaigns can alleviate the threats of cholera.
Sections du résumé
BACKGROUND
Bangladesh experienced a sudden, large influx of forcibly displaced persons from Myanmar in August 2017. A cholera outbreak occurred in the displaced population during September-December 2019. This study aims to describe the epidemiologic characteristics of cholera patients who were hospitalized in diarrhea treatment centers (DTCs) and sought care from settlements of Forcibly Displaced Myanmar Nationals (FDMN) as well as host country nationals during the cholera outbreak.
METHODS
Diarrhea Treatment Center (DTC) based surveillance was carried out among the FDMN and host population in Teknaf and Leda DTCs hospitalized for cholera during September-December 2019.
RESULTS
During the study period, 147 individuals with cholera were hospitalized. The majority, 72% of patients reported to Leda DTC. Nearly 65% sought care from FDMN settlements. About 47% of the cholera individuals were children less than 5 years old and 42% were aged 15 years and more. Half of the cholera patients were females. FDMN often reported from Camp # 26 (45%), followed by Camp # 24 (36%), and Camp # 27 (12%). Eighty-two percent of the cholera patients reported watery diarrhea. Some or severe dehydration was observed in 65% of cholera individuals. Eighty-one percent of people with cholera received pre-packaged ORS at home. About 88% of FDMN cholera patients reported consumption of public tap water. Pit latrine without water seal was often used by FDMN cholera individuals (78%).
CONCLUSION
Vigilance for cholera patients by routine surveillance, preparedness, and response readiness for surges and oral cholera vaccination campaigns can alleviate the threats of cholera.
Identifiants
pubmed: 34550972
doi: 10.1371/journal.pntd.0009618
pii: PNTD-D-21-00136
pmc: PMC8457470
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009618Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2019 Jun 20;13(6):e0007347
pubmed: 31220084
Br Med J (Clin Res Ed). 1982 Oct 23;285(6349):1185-8
pubmed: 6812801
Am J Trop Med Hyg. 2020 Aug;103(2):652-658
pubmed: 32458788
Vaccine. 2020 Feb 29;38 Suppl 1:A127-A131
pubmed: 31301917
Annu Rev Public Health. 1997;18:283-312
pubmed: 9143721
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD008603
pubmed: 21412922
Int J Environ Res Public Health. 2017 Aug 21;14(8):
pubmed: 28825673
Emerg Infect Dis. 2016 Jun;22(6):1067-70
pubmed: 27192187
Science. 2019 Apr 12;364(6436):138
pubmed: 30975880
Lancet. 2017 Nov 18;390(10109):2233-2242
pubmed: 29165262
Hum Vaccin Immunother. 2019;15(12):2882-2886
pubmed: 31441679
Lancet. 2017 Feb 25;389(10071):802-803
pubmed: 28248175
PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0007989
pubmed: 32176695
Trop Med Int Health. 2016 Feb;21(2):194-201
pubmed: 26681205
BMJ. 2017 Nov 15;359:j5210
pubmed: 29141900
Lancet. 2018 May 12;391(10133):1877-1879
pubmed: 29781432
Vaccine. 2013 Jan 7;31(3):452-60
pubmed: 23153448
J Infect Dev Ctries. 2013 Dec 15;7(12):900-9
pubmed: 24334935
Lancet. 2004 Nov 27-Dec 3;364(9449):1974-83
pubmed: 15567014
BMC Infect Dis. 2014 Aug 15;14:440
pubmed: 25127553
BMC Biol. 2010 Oct 04;8:129
pubmed: 20920375
J Glob Health. 2018 Dec;8(2):020309
pubmed: 30410735
Emerg Infect Dis. 2018 Nov;24(11):2074-2076
pubmed: 30234479
Expert Rev Anti Infect Ther. 2012 Apr;10(4):435-44
pubmed: 22512753